What You Should Know:
– Tempus AI, a leader in artificial intelligence (AI)-powered precision medicine, filed with the Securities and Exchange Commission (SEC) on Monday to raise up to $100M in an initial public offering (IPO). Industry analysts, however, believe this figure might be a placeholder, with the actual target amount closer to $600M.
– Founded in 2015 and headquartered in Chicago, Illinois, Tempus AI reported $562M in revenue for the fiscal year ending March 31, 2024.
Unlocking the Power of Precision Medicine
The company plans to list on the Nasdaq under the ticker symbol TEM. Notably, Tempus AI initially filed confidentially for the IPO on September 1, 2021. They also rebranded from Tempus Labs to Tempus AI in December 2023. Tempus AI focuses on harnessing the potential of AI to revolutionize healthcare. Through its proprietary Tempus Platform, the company combines cutting-edge software with dedicated data pipelines. This network connects over 2,000 healthcare institutions through approximately 450 unique data connections. This innovative technology has enabled Tempus to build what they claim is one of the world’s largest libraries of clinical and molecular oncology data.
Financial Backing and Next Steps
The IPO will be led by a team of joint bookrunners, including prominent investment banks like Morgan Stanley, J.P. Morgan, Allen & Company, BofA Securities, TD Cowen, Stifel, and William Blair. While specific pricing details haven’t been disclosed yet, the industry expects a significant offering.
This IPO filing signifies Tempus AI’s intention to leverage public capital to further its mission of advancing precision medicine through its AI-powered platform. With its impressive revenue growth and vast data library, Tempus AI seems poised to make a splash on the public market.
